This application note presents an independent cost-of-goods (COG) analysis conducted by Decisional Point Limited to evaluate the financial impact of switching from plasmid DNA (pDNA) to Touchlight’s enzymatically produced dbDNA™ for AAV manufacturing. Leveraging an established AAV bioprocess economic model, the study compares baseline COG for dbDNA™ versus pDNA and explores multiple scenario analyses, including dose size, GMP DNA cost, and transfection material requirements to assess their influence on total COG, COG per dose, and COG across key process steps.

The results demonstrate a significant reduction in manufacturing COG when using dbDNA™, highlighting meaningful potential savings for AAV gene therapy developers.

Download the application note to explore the complete analysis and findings.